Ironwood Pharmaceuticals Inc’s Sentiment

In 2018 Q4 Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) big money sentiment increased to 1.07, SEC filings reveal. So its up 0.10, from 2018Q3’s 0.97. 65 active investment managers increased or opened new equity positions, while 61 sold and reduced equity positions in Ironwood Pharmaceuticals Inc so the sentiment increased. These funds own 140.64 million shares, that’s down from 142.30 million shares in 2018Q3. Funds holding Ironwood Pharmaceuticals Inc in top 10 changed to 2 from 3 for a decrease of 1. 25 Investors Sold All; 36 Reduced Holdings; 39 increased holdings while 26 active investment managers bought holdings.

Biggest Ironwood Pharmaceuticals Inc Investors

As of 2018 Q4 Sarissa Capital Management Lp has 14.35% invested in Ironwood Pharmaceuticals Inc. As of 2018 Q4, 5.38 million shares of Ironwood Pharmaceuticals Inc are owned by Ecor1 Capital Llc. In addition, Bridger Management Llc reported 4.18 million shares in Ironwood Pharmaceuticals Inc equivalent to 3.61% of its stocks portfolio. Broderick Brian C revealed 329,233 shares position in Ironwood Pharmaceuticals Inc. The Maryland-based fund Brown Capital Management Llc looks positive on Ironwood Pharmaceuticals Inc, having 10.13 million shares.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products.The company has $2.12 billion market cap. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names.Last it reported negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

IRWD hit $13.69 during the last trading session after $0.4 change.Currently Ironwood Pharmaceuticals, Inc. is downtrending after 2.58% change in last March 11, 2018. IRWD has 212,406 shares volume. The stock underperformed the S&P 500 by 6.95%.

On May, 7 is awaited Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s earnings report, as reported by RTT. Analysts forecast 55.56 % diference or $-0.12 from the $-0.27 EPS from 2018. After $-0.02 earnings per share was published last quarter, analysts now see negative EPS growth of 500.00 % for Ironwood Pharmaceuticals, Inc..

Tiaa Cref Invest Management Limited Liability Co invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Ohio-based Fifth Third Bank has invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Ameritas Invest Ptnrs Inc, Nebraska-based fund reported 11,821 shs. Hap Trading Limited Company holds 0.02% of its capital in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 25,261 shs. Price T Rowe Associates Md holds 3.09 million shs or 0.01% of its capital. Tocqueville Asset Management L P has invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Alliancebernstein L P owns 0% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 202,560 shs. Ontario Teachers Pension Plan Board has invested 0.03% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Jefferies Grp Ltd invested in 0% or 12,032 shs. California State Teachers Retirement Sys stated it has 0.01% of its capital in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Royal London Asset Mgmt has invested 0.02% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Quantitative Invest Limited Com owns 67,600 shs. Commercial Bank Of New York Mellon accumulated 610,753 shs. Royal National Bank & Trust Of Canada reported 2,672 shs. First Trust Advsr L P has 0% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).

Ironwood Pharmaceuticals, Inc. registered $5.34 million net activity with 0 buys and 5 sales since October 4, 2018. McHugh Julie sold 1,500 shs worth $18,690. Hecht Peter M also sold $1.12 million worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shs. $16,038 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was sold by Consylman Gina on Friday, November 9. On Thursday, October 4 Currie Mark G had sold 233,301 shs worth $4.16 million.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage

In total 4 analysts cover Ironwood Pharmaceuticals (NASDAQ:IRWD). “Buy” rating has 1, “Sell” are 0, while 3 are “Hold”. (NASDAQ:IRWD) has 25% bullish analysts. 6 are the (NASDAQ:IRWD)’s ratings reports on 11 Mar 2019 according to StockzIntelligence Inc. On Monday, February 25 the firm earned “Neutral” rating by H.C. Wainwright. The company rating was downgraded by JP Morgan on Wednesday, November 7. On Thursday, January 24 JP Morgan upgraded Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rating. JP Morgan has “Neutral” rating and $13 target. On Friday, February 22 the stock has “Buy” rating by Mizuho. On Wednesday, November 7 the rating was downgraded by Credit Suisse to “Neutral”.

For more Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news brought out briefly go to: Seekingalpha.com, Seekingalpha.com, Benzinga.com, Globenewswire.com or Benzinga.com. The titles are as follows: “Pernix Therapeutics leads healthcare gainers; Natus Medical and Cambrex among losers – Seeking Alpha” brought out on February 13, 2019, “Ironwood Pharmaceuticals Q4 2018 Earnings Preview – Seeking Alpha” on February 12, 2019, “58 Biggest Movers From Yesterday – Benzinga” with a publish date: February 14, 2019, “Recent Analysis Shows Yamana Gold, Broadcom Inc., Atlas Air Worldwide, Hawaiian, H&E Equipment Services, and Ironwood Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth – GlobeNewswire” and the last “42 Stocks Moving In Wednesday’s Mid-Day Session – Benzinga” with publication date: February 13, 2019.